An Investigational B-Cell Modulator for the Treatment of Autoimmune Renal Disease
- Discuss the central role of B-cells, BAFF and APRIL in the pathophysiology of IgAN
- Review the MOA of atacicept and its potential role in IgAN and other antibody mediated glomerular disorders
- Provide and overview of the ORIGIN atacicept clinical development program including recent phase 3 data